Gebo KA - Search Results

1

Retention among North American HIV-infected persons in clinical care, 2000-2008.

Rebeiro P, Althoff KN, Buchacz K, Gill J, Horberg M, Krentz H, Moore R, Sterling TR, Brooks JT, Gebo KA, Hogg R, Klein M, Martin J, Mugavero M, Rourke S, Silverberg MJ, Thorne J, Gange SJ; North American AIDS Cohort Collaboration on Research and Design. Rebeiro P, et al. Among authors: gebo ka. J Acquir Immune Defic Syndr. 2013 Mar 1;62(3):356-62. doi: 10.1097/QAI.0b013e31827f578a. J Acquir Immune Defic Syndr. 2013. PMID: 23242158 Free PMC article.

2

Risk factors for pneumococcal disease in human immunodeficiency virus-infected patients.

Gebo KA, Moore RD, Keruly JC, Chaisson RE. Gebo KA, et al. J Infect Dis. 1996 Apr;173(4):857-62. doi: 10.1093/infdis/173.4.857. J Infect Dis. 1996. PMID: 8603963

3

Costs of HIV medical care in the era of highly active antiretroviral therapy.

Gebo KA, Chaisson RE, Folkemer JG, Bartlett JG, Moore RD. Gebo KA, et al. AIDS. 1999 May 28;13(8):963-9. doi: 10.1097/00002030-199905280-00013. AIDS. 1999. PMID: 10371178

4

Hospitalization rates in an urban cohort after the introduction of highly active antiretroviral therapy.

Gebo KA, Diener-West M, Moore RD. Gebo KA, et al. J Acquir Immune Defic Syndr. 2001 Jun 1;27(2):143-52. doi: 10.1097/00126334-200106010-00009. J Acquir Immune Defic Syndr. 2001. PMID: 11404536

5

Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic.

Lucas GM, Gebo KA, Chaisson RE, Moore RD. Lucas GM, et al. Among authors: gebo ka. AIDS. 2002 Mar 29;16(5):767-74. doi: 10.1097/00002030-200203290-00012. AIDS. 2002. PMID: 11964533

6

Association of social stress, illicit drug use, and health beliefs with nonadherence to antiretroviral therapy.

Gebo KA, Keruly J, Moore RD. Gebo KA, et al. J Gen Intern Med. 2003 Feb;18(2):104-11. doi: 10.1046/j.1525-1497.2003.10801.x. J Gen Intern Med. 2003. PMID: 12542584 Free PMC article.

7

Hospitalization rates differ by hepatitis C satus in an urban HIV cohort.

Gebo KA, Diener-West M, Moore RD. Gebo KA, et al. J Acquir Immune Defic Syndr. 2003 Oct 1;34(2):165-73. doi: 10.1097/00126334-200310010-00006. J Acquir Immune Defic Syndr. 2003. PMID: 14526205

8

The HIV Research Network: a unique opportunity for real time clinical utilization analysis in HIV.

Gebo KA, Moore RD, Fleishman JA. Gebo KA, et al. Hopkins HIV Rep. 2003 Nov;15(6):5-6. Hopkins HIV Rep. 2003. PMID: 14974424 No abstract available.

9

The epidemiology, treatment patterns, and costs of cytomegalovirus retinitis in the post-haart era among a national managed-care population.

Mahadevia PJ, Gebo KA, Pettit K, Dunn JP, Covington MT. Mahadevia PJ, et al. Among authors: gebo ka. J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):972-7. doi: 10.1097/00126334-200408010-00012. J Acquir Immune Defic Syndr. 2004. PMID: 15220705

10

Absolute CD4 vs. CD4 percentage for predicting the risk of opportunistic illness in HIV infection.

Gebo KA, Gallant JE, Keruly JC, Moore RD. Gebo KA, et al. J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1028-33. doi: 10.1097/00126334-200408150-00005. J Acquir Immune Defic Syndr. 2004. PMID: 15247555

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

265 results

Search Page

Filters